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ABSTRACT
Uveal melanoma (UM) is the most common malignant tumor of the eye. Recently, 
we have established that 46% of UM specimens express LHRH receptors. This finding 
supports the idea of a LHRH receptor-targeted therapy of UM patients. Cytotoxic 
analog of LHRH, AEZS-108 exhibits effective anti-cancer activity in LHRH-receptor 
positive cancers. AEZS-108 is a hybrid molecule, composed of a synthetic peptide 
carrier and the cytotoxic doxorubicin (DOX). In the present study, we investigated 
AEZS-108 induced cytotoxicity and the altered mRNA expression profile of regulatory 
factors related to angiogenesis and metastasis in LHRH receptor positive OCM3 cells. 
Our results show that AEZS-108 upregulates the expression of MASPIN/SERPINB5 
tumor suppressor gene, which is downregulated in normal uvea and UM specimens 
independently from the LHRH receptor-ligand interaction. AEZS-108 also substantially 
downregulates hypoxia-inducible factor 1 alpha (HIF1A) expression. In order to 
investigate the mechanism of the induction of MASPIN by AEZS-108, OCM3 cells 
were treated with free DOX, D-Lys6 LHRH analog, or AEZS-108. qRT- PCR analysis 
revealed in OCM3 cells that AEZS-108 is a more potent inducer of MASPIN than free 
DOX. In conclusion, we show for the first time that AEZS-108 has a major impact in 
the regulation of angiogenesis thus plays a potential role in tumor suppression. Taken 
together, our results support the development of novel therapeutic strategies for UM 
focusing on LHRH receptors.
INTRODUCTION
Although uveal melanoma (UM) is a rare disease, 
it is the most prevalent lethal ophthalmological tumor [1, 
2]. Approximately 50% of the patients already manifests 
distant metastases, mostly in the liver at the time of the 
diagnosis [2]. In spite of the currently available systemic 
therapies, 90% of the patients with metastasis die within 
1 year of the diagnosis of UM [3, 4]. Chemotherapy or 
partial hepatectomy only rarely prolongs the survival, 
emphasizing the necessity of developing more effective 
therapies [5].
The discovery of specific receptors for peptide 
hormones on cancer cells has led to the development 
of cytotoxic or radiolabeled hormone analogs that are 
appropriate for tumor localization and targeted therapy. 
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Numerous preclinical studies have demonstrated the 
efficacy of chemotherapy based on cytotoxic peptide 
conjugates targeted to receptors on different tumors 
[6–10]. Clinical trials confirmed that targeted cytotoxic 
LHRH analog can improve the effectiveness of treatment 
and reduce general side effects [11–13].
Luteinizing Hormone-Releasing Hormone (LHRH) 
and its receptor (LHRH-R) are not limited to the 
hypothalamic-pituitary axis [14–18]. In the periphery, the 
LHRH system regulates gonadal functions and appears to 
serve as a growth factor of benign prostate hyperplasia 
[10, 19–21] and even in various cancers, including breast, 
lung, ovary, endometrial, urinary, colon, pancreas and 
prostate cancer [22–31].
In our previous study, we have revealed that more than 
40% of human uveal melanomas express LHRH receptor 
type I [1]. AEZS-108 (formerly known as AN-152 / INN: 
Zoptarelin Doxorubicin Acetate) is a targeted cytotoxic 
LHRH-analog consisting of doxorubicin conjugated to 
D-Lys6 LHRH. AEZS-108 guides the chemotherapeutic agent 
specifically to those tumors that express LHRH-receptors, 
which could result in targeted cytotoxicity and less damage 
to healthy tissues [9, 11, 13, 30, 32]. AEZS-108 has been 
utilized in phase III clinical trials in advanced, recurrent or 
metastatic endometrial cancer, in phase I-II in castration 
resistant prostate cancer and ovarian cancer [9, 11, 13, 32]. 
Moreover, AEZS-108 was found to be able to inhibit the 
growth of doxorubicin resistant cells [31, 33].
In the present study our aim was to demonstrate 
the antitumor effects of AEZS-108 in a human uveal 
melanoma cell line. As we reported it previously OCM3 
UM cell line express the receptor of LHRH localized on 
the cell membrane and in the cytoplasm, rendering them 
susceptible to AEZS-108 uptake [33, 34]. The detection of 
LHRH receptor in OCM3 cells has led to use AEZS-108 
for targeted therapy of the tumor. Our results shows that 
AEZS-108, as well as doxorubicin significantly inhibited 
the proliferation of OCM3 human uveal melanoma cells. 
Angiogenesis has a pivotal role in the development of 
UM because lymphatic vessels are not present in the 
eye to promote distant metastasis [35, 36]. This special 
characteristics of UM also led us to investigate the effect 
of AEZS-108 on the expression of the genes involved in 
angiogenesis and metastasis in an in vitro model of UM. 
The qRT-PCR array results showed that AEZS-108 altered 
the expression of MASPIN, HIF1A and its target genes. 
Furthermore, qRT-PCR analysis revealed that AEZS-108 
is a more potent inducer of MASPIN tumor suppressor than 
free DOX in OCM3 cells. MASPIN has been shown to be 
downregulated in normal uvea and UM tumor specimens.
Western blot analysis confirmed that the greatest 
changes of mRNA expression are at protein levels as well. 
To conclude, we report here, that OCM3 UM cell line 
expresses the LHRH receptor and LHRH rendering them 
susceptible to AEZS-108 uptake. AEZS-108 treatment 
resulted in changes in the expression of genes involved 
in the extracellular matrix (ECM) remodelling and 
angiogenesis. Our findings support the novel notion that 
AEZS-108 might be suitable as a potential drug candidate 
in targeted therapy of uveal melanoma.
RESULTS
OCM3 human uveal melanoma cell line 
expresses the human LHRH receptor type I
Expression and cellular distribution of the full length 
LHRH receptor type I in OCM3 cells was demonstrated 
by RT-PCR and by immunocytochemistry (Figure 1). 
The expected 319 bp PCR product, amplified with gene 
specific primers, was detected successfully in OCM3 cell 
line. Our result was confirmed also at protein levels by 
immunocytochemistry. We found that full length LHRH 
receptors are present in the cell membrane and therefore in 
the cytoplasm, so they might play a role in the facilitation 
of the selective uptake of AEZS-108 in OCM3 cells.
AEZS-108 and doxorubicin induces comparable 
cytotoxicity in OCM3 cells
In order to investigate whether AEZS-108 inhibits 
cell proliferation and its extent, OCM3 cells were 
treated either with 5 µM AEZS-108 or equal amount of 
doxorubicin. MTS assay was performed after 24 and 48 
hours of treatment. AEZS-108 and doxorubicin have been 
shown to reduce cell proliferation by 36.3% (p < 0.001) 
and 62.9% (p < 0.001) respectively after 24 hours, and 
by 84.7% (p < 0.001) and 89.7% (p < 0.001) respectively 
after 48 hours, (Figure 2).
AEZS-108 alters the expression of angiogenesis 
and metastatis regulatory factors in OCM3 cells
We have investigated the role of AEZS-108 in 
the expression of 94 key regulatory genes involved in 
angiogenesis and development of metastasis in OCM3 
cells. MASPIN (SERPINB5), SERPINE1 (PAI-1), 
CXCR4, VEGFA and MAPK7 genes have been found to 
be significantly upregulated, while ANGPT1, HIF1A, 
ANGPTL3, ETS1, VEGFB, CEACAM and SURVIVIN 
genes were significantly downregulated (p < 0.05) 
as compared to control (untreated) cells. The tumor 
suppressor gene MASPIN (SERPINB5) showed the 
highest overexpression (203.19× upregulation), while the 
most significantly downregulated gene was HIF1A (8.67× 
downregulation) (Tables 1 and 2).
AEZS-108 provokes higher expression of 
MASPIN than free DOX
The expression of MASPIN tumor suppressor gene 
was further investigated by qRT-PCR. OCM3 cells were 
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Figure 1: (A) Strong positivity of the full length LHRH receptor as detected by specific antibody in the nucleus, in the cytoplasm and in 
the membrane by DAB-immunoperoxidase staining. (B) Insert is a negative control for the staining-specificity. Original magnifications 
of images in immuncitochemistry: 40 ×. (C) Expression of LHRH receptor type I in OCM3 human uveal melanoma cells. The expected 
PCR products amplified with gene specific primers with 319 bp were detected successfully in OCM3 cell line. DNA ladder: 50 bp ladder 
(Fermentas), +: positive control (human pituitary); –: no template control, No. 1–6: representative human uveal melanoma tissues.
Figure 2: The cytotoxicity of AEZS-108 and DOX in OCM3 cells. The effect of treatment with 5 µM AEZS-108 and 5 µM DOX 
for 24 and 48 hours on cell viability of OCM3 cells was measured by MTS assay in complete medium. Statistical analysis was performed 
by one-way ANOVA (**: highly significant, p < 0.01; ***: extremely significant, p < 0.005).
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treated with AEZS-108, D-Lys6 LHRH analog or free 
DOX. Our results clearly showed that D-Lys6 LHRH-
treated cells do not express MASPIN, while free DOX and 
AEZS-108 induces MASPIN expression. However, equal 
dose of AEZS-108 and DOX show significantly different 
effect on MASPIN expression, namely, that AEZS-
108 treatment results in significantly higher MASPIN 
expression than free DOX treatment (Figure 3).
The tumor suppressor MASPIN is not expressed 
in uveal melanoma or in normal uvea tissue 
specimens
The mRNA expression of MASPIN has been 
investigated in 3 healthy and 18 human uveal melanoma 
tissue specimens by real time PCR. Our results did not 
show mRNA expression of MASPIN in healthy or in uveal 
melanoma tissues (data not shown).
AEZS-108 alters MASPIN, HIF1A, VEGFA and 
VEGFB protein expression in OCM3 cells
Protein levels of MASPIN, HIF1A, VEGFA and 
VEGFB have also been examined. SDS PAGE Western 
blot analysis confirmed the qRT-PCR results, namely, that 
MASPIN production in untreated OCM3 cells is very low, 
however, treatment with AEZS-108 or free DOX slightly 
increases the expression of MASPIN tumor suppressor 
(Figure 4). As seen at mRNA and protein levels, AEZS-
108 is a more potent inducer of MASPIN than free DOX. 
Furthermore, in order to unravel whether AEZS-108 
or free DOX has an effect on angiogenesis, HIF1A and 
its target proteins, VEGFA and VEGFB angiogenesis 
related proteins were also investigated. Our data showed 
that treatment with AEZS-108 and DOX significantly 
decreased HIF1A, VEGFA and VEGFB expression 
(Figure 4).
DISCUSSION
Although uveal melanoma is very rare, it is the 
most common primary intraocular malignant cancer and 
the second most common primary malignant melanoma 
in humans [4]. Death usually occurs within a year of 
the onset of systemic symptoms [3, 4]. The liver is a 
virtual “sentinel lymph node” for uveal melanoma since 
unfortunately it is involved in 95% of patients with 
metastasis [4]. The absence of effective therapy for 
Table 1: In vitro results of significantly upregulated genes following 5 µM AEZS-108 treatment in 
OCM3 cells
Symbol of gene Upregulation (treated/control) p value
MASPIN (SERPINB5) +203.19 0.0021
SERPINE1(PAI1) +52.59 0.0109
CXCR4 +15.45 0.0052
VEGFA +3.48 0.0005
MAPK7 +2.27 0.0354
Results were normalized by the Global Pattern Recognition algorithm (Bar Harbor BioTechnology Inc.’s, USA), and quantified 
by ∆∆Ct method. Differences between the expression of genes between groups were tested for statistical significance level 
using Student’s t-test. (significant: p < 0.05).
Table 2: In vitro results of significantly downregulated genes following treatment with 5 µM AEZS-
108 in OCM3 cells
Symbol of gene Downregulation (treated/control) p value
ANGPT1 –32.00 0.0220
HIF1A –8.67 0.0187
ANGPTL3 –6.57 0.0433
ETS1 –5.66 0.0036
VEGFB –5.10 0.0230
CEACAM1 –4.14 0.0082
SURVIVIN –3.91 0.0007
Results were normalized by the Global Pattern Recognition algorithm (Bar Harbor BioTechnology Inc.’s, USA), and quantified 
by ∆∆Ct method. Differences between the expression of genes between groups were tested for statistical significance level 
using Student’s t-test. (significant: p < 0.05).
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metastatic disease offers now a chessboard for targeted 
therapy, creating new opportunities to develop novel 
treatment options [36–40].
It has been shown that the growth of various 
cancer cell lines, e. g. cutaneous melanoma xenografted 
into nude mice can be inhibited by analogs of targeted 
cytotoxic luteinizing-hormone-releasing hormone 
(LHRH) [41]. Interestingly, our previous results showed 
that 46% of specimens of uveal melanoma tissues 
express LHRH receptor type I [1]. Previous studies have 
demonstrated that AEZS-108 strongly inhibits the growth 
of experimental human prostatic, mammary, ovarian and 
urinary bladder cancers as well as melanomas expressing 
LHRH receptors [6, 12, 27, 30, 32, 33, 41, 42]. Previous 
in vivo investigations have demonstrated that AEZS-108 
has a prominent antitumor activity and less toxicity than 
unconjugated DOX in various cancer types [7–9, 11–13, 
43]. Upon detection of LHRH receptors in specimens of 
human uveal melanoma, we have investigated whether 
AEZS-108, which is appropriate for targeted therapy of 
various tumors, could serve as a novel therapy in UM.
Our aim was to further elucidate the antitumor 
effects of AEZS-108 in human UM. As a relevant in vitro 
model of UM, OCM3 cell line was selected in order to 
investigate the antitumor-effect of AEZS-108 compared 
to its unconjugated cytotoxic consituent, doxorubicin. 
First, we examined the expression of LHRH receptors in 
OCM3 cells by qRT-PCR and by immunocytochemistry. 
To demonstrate if AEZS-108 induces cytotoxicity, OCM3 
cells were treated with 5 µM AEZS-108 or equal amount 
of doxorubicin and then MTS-assay was performed. Our 
result show that AEZS-108 reduces cell viability by 36.3% 
after 24 hours (p < 0.001) and by 84.7% after 48 hours (p 
< 0.001). In contrast, free DOX led to 62.9% (p < 0.001) 
and 89.7% (p < 0.001) cell death after 24 and 48 hours, 
respectively. These results might be explained by the fact, 
established previously, that some cytotoxic ligand analogs 
containing DOX show ten times lower antiproliferative 
activity in vitro than doxorubicin. However, in vivo 
experiments are in accord with the in vitro results and 
demonstrate that cytotoxic ligand analogs present high 
antitumor activity, greater efficacy and less toxicity than 
doxorubicin [7–9, 32].
Since lymphatic vessels are absent in the eye, 
angiogenesis plays a pivotal role in the development of 
UM and subsequently, in the development of metastasis 
[35, 36, 44, 45]. Based on the special characteristics of 
uveal melanoma, our further aim was to investigate the 
effect of AEZS-108 on the expression of the genes related 
to angiogenesis and migration in OCM3 cells by qRT-
Figure 3: Treatment with AEZS-108 at equal doses with DOX was significantly more effective in the upregulation of 
MASPIN than free DOX. The expression of MASPIN tumor suppressor was measured by qRT-PCR from three independent experiments. 
For comparison, the corresponding mRNA expression levels of MASPIN are shown below the qPCR graphs for each treatments. Statistical 
analysis was performed by one-way ANOVA (*: significant, p < 0.05; ***: extremely significant, p < 0.005).
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Figure 4: Western blot analysis of MASPIN, HIF1A, VEGFA and VEGFB protein expression after 24 hours of 
treatment with 5 µM AEZS-108 and 5 µM free DOX treatments from OCM3 cells. 40 µg of protein from each sample was 
separated on 12% SDS PAGE and transferred to PVDF or nitrocellulose membranes and probed with specific antibodies (described in 
Materials and metods). Data represents the densitometric analysis of the results to the target proteins normalized to β-actin or GAPDH. 
Statistical analysis was performed by one-way ANOVA (*: significant, p < 0.05).
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PCR array. The tumor suppressor MASPIN (SERPINB5) 
and SERPINE1 genes showed the highest overexpression, 
while the most significantly downregulated genes were 
HIF1A and its target genes, also involved in angiogenesis 
and metastasis of cancer cells. The observed changes in 
mRNA expression have been confirmed at protein level 
by Western blot analysis.
In terms of function these findings support a central 
role for MASPIN and HIF1A in ECM and in the regulation 
of angiogenesis in UM whereas the published data on role 
of these two genes for the survival of UM is relatively 
limited [46, 47].
Previous studies have demonstrated the role of 
MASPIN and SERPINE1 in the coordination of ECM 
proteolytic system and its important functions in cell 
migration, proliferation and survival [46]. MASPIN and 
SERPINE1 are natural inhibitors of uPA/uPAR signaling, 
which is strengthened during inflammation, tissue 
remodeling and in many cancers, frequently indicating 
a poor prognosis [46] (Figure 5). We have detected that 
both MASPIN and SERPINE1, uPAR signaling inhibitors 
were simultaneously upregulated by treatment with 
AEZS-108. Controversially, HIF1A, the central regulator 
of angiogenesis was downregulated. HIF1A induces 
tumor hypoxia driving uPAR expression through a 
hypoxia responsible element (HRE) in the uPAR promoter. 
Furthermore, uPAR is required for the induction of an 
epithelial-mesenchymal transition-like response in other 
cancer cell lines following exposure to hypoxia [46, 
48]. Previously demonstrated data in accordance with 
our results might suggest that AEZS-108 induces a well 
regulated signaling pathway against ECM degradation, 
angiogenesis and migration of tumor cells via the 
regulation of MASPIN, HIF1A and their target genes [46].
In order to investigate the mechanism of the induction 
of MASPIN, OCM3 cells were treated with free DOX, 
D-Lys6 LHRH analog, or AEZS-108. AEZS-108 induced 
greater MASPIN expression compared to free DOX. 
Unconjugated D-Lys6 LHRH analog had no effect on the 
induction of MASPIN. Based on our results, we assume 
that the induction of MASPIN is independent of the LHRH 
ligand-receptor interaction, and is probably triggered only 
by the cytotoxic DOX unit. The upregulation of MASPIN 
expression might be explained by a probable decrease in 
transporter activity in the presence of AEZS-108 [49].
We have also evaluated the expression of MASPIN 
expression in healthy human uvea and in human UM 
tissue specimens. According to our results, MASPIN 
is undetectable in healthy uvea and in UM tissues. 
Diminished expression of MASPIN in the UM specimens 
is congruent with a previous study, in which the decreased 
MASPIN expression in UM tissue specimens indicated 
poor prognosis due to therapy resistance [50].
In summary, our data confirmed previous results 
showing LHRH receptor expression in OCM3 cells, an 
UM in vitro model. Furthermore, we report for the first 
time that AEZS-108 causes changes in the expression 
of genes which are involved in angiogenesis and ECM 
degradation and which might inhibit cell proliferation and 
induce apoptosis in OCM3 cells.
Figure 5: MASPIN can prevent the formation of UPA - UPA-receptor complex by a single step, and thus decrease the 
possibility of the abnormal degradation of the ECM, the development metastasis and angiogenesis. (UPA: urokinase type 
plasminogen activator, UPAR: UPA-receptor, HIF1A: hypoxia-inducible factor 1 alpha ECM: extracellular matrix, RAS: GTP-binding 
protein, RAC: subfamily of RHO-GTP-ases).
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These findings suggest that AEZS-108 plays a 
pivotal role in the regulation of angiogenesis and tumor 
suppression. Taken together, targeted cytotoxic LHRH 
analogs, such as AEZS-108, might serve as an effective 
treatment for patients with LHRH receptor positive uveal 
melanoma.
MATERIALS AND METHODS
Ethics statement
The local Institutional Ethics Committee of the 
University of Debrecen approved the collection and use 
of human pituitary, normal uvea and uveal melanoma 
specimens for the current study and informed consent 
was obtained from these patients (ID number: DERKEB/
IKEB 4172-2014). Uvea and uveal melanoma specimens 
were obtained at the time of initial surgical treatment at the 
Department of Ophthalmology, University of Debrecen, 
Hungary. Normal pitutaries were collected by autopsy at 
the Department of Pathology, University of Debrecen, 
Hungary.
Cell line and culturing conditions
The human metastatic uveal melanoma cell line, 
OCM3 (ocular choroideal melanoma 3, cultured from 
primary tumor) was kindly provided by the Department 
of Biophysics and Cell Biology, Faculty of Medicine, 
University of Debrecen. OCM3 cells were cultured 
in complete growth medium: RPMI 1640 medium 
supplemented with L-glutamine (PPA Labotatories, 
Austria), 10% fetal bovine serum (FBS) (PPA 
Labotatories, Austria) and 100 U/ml Penicillin, 100 mg/
ml Streptomycin (Pen/Strep, TEVA Pharmaceuticals Zrt., 
Hungary) in a humidified chamber (95% air humidity, 5% 
CO2) at 37°C.
Detection of LHRH receptor in OCM3 cells by 
immunocytochemistry
Cells were seeded into a 96-well plate at the density 
of 25.000 cells/well in complete growth medium and 
were left to adhere overnight. On the following day, 
cells were rinsed with PBS (pH 7.4) and fixed in cold 
methanol for 10 minutes. Endogenous peroxidase activity 
was blocked with 3% H2O2. Cells were permeabilized by 
adding 0.1% Triton X-100 in PBS. Non-specific binding 
sites were blocked with 1% FBS and 0.1% Triton X-100 
containing PBS (60 min, room temperature). Cells were 
incubated with human LHRH receptor type I antibody 
(Santa Cruz Biotechnology, USA, FL-328; sc-13944) 
in 1:100 dilution in PBS overnight at 4°C. Next day, 
cells were stained with horseradish peroxidase (HRP)-
conjugated secondary antibody (anti-rabbit IgG (Fab) of 
EnVision+ kit, (DM822) Dako, Denmark) according to 
the manufacturer’s instructions. Human pituitary glands 
(anterior lobe) obtained from autopsy at the University of 
Debrecen were used as positive controls.
Negative controls (primary antibody was replaced 
by normal serum) were also included. DAB chromogenic 
staining of the receptors was detected by SPOT™ 
Imaging Software (Dioganostic Instruments Inc., 
USA) and Nikon Eclipse TS/100 microscope (Nikon 
Instruments, Melville, NY).
Detection of LHRH receptor type I in OCM3 
cells after RNA isolation by reverse transcription 
(RT)-PCR
Total RNA was isolated from OCM3 cells using 
the AllPrep DNA/RNA/Protein Mini kit (Qiagen, 
Germany). 500 ng of RNA from each sample was 
reverse transcribed into cDNA by QuantiTect Reverse 
Transcription kit (Qiagen, Germany). The following 
primer pair has been used to detect LHRH-R type I: 5′- 
GAC CTT GTC TGG AAA GAT CC -3′ (sense), 5′- CAG 
GCT GAT CAC CAC CAT CA -3′ (antisense) (Sigma-
Aldrich Corporation, USA). Primers were designed using 
Primer3web softwer. One μl of cDNA was amplified in a 
25 μl solution containing 1.5 mM MgCl2, 1× PCR buffer 
(Fermentas, Germany), 0.3 mM of each deoxynucleotide 
(Promega, Germany), 1 unit of TrueStart HotStart DNA 
polymerase (Fermentas, Germany) and 0.25 μM of each 
primer. Samples were subjected to 40 cycles of 95°C for 
45 s, 59°C for 30 s, then 72°C for 1.5 min with a final 
extension of 10 min at 72°C. Normal human pituitaries, 
collected at autopsy, served as positive control. Human 
uveal melanoma specimens, previously investigated 
by us [1] were also used to confirm the expression of 
LHRH receptors. No template control (NTC) was used to 
detect potential contaminations in the RT-PCR reactions. 
PCR cycles have been performed using the Bio-Rad 
C1000™ Thermal Cycler (Bio-Rad Laboratories, USA) 
instrument. 10 μl of each amplification reaction was then 
electrophoretically separated on 1.5% agarose gel, stained 
with GelRed (Biotinum, USA), and visualized under UV 
light.
Cytotoxic and LHRH ligand analogs and 
doxorubicin
The targeted cytotoxic analog, AEZS-108 (formerly 
known as AN-152/ INN: Zoptarelin Doxorubicin Acetate), 
corresponding to D-Lys6 LHRH (pyroGlu-His-Trp-Ser-
Tyr-D-Lys-Leu-Arg-Pro-Gly-NH2) linked to doxorubicin 
(DOX) was first sythesized by solid-phase method, as 
described by the laboratory of Andrew V. Schally [6, 7, 42]. 
The AEZS-108 and D-Lys6 LHRH used in our experiments 
was kindly provided by AEterna/ Zentaris (Frankfurt am 
Main, Germany). Doxorubicin-HCl (2 mg/ml) (DOX) was 
purchased from Teva Pharmaceutical Works Ltd. (Hungary).
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The compounds were dissolved in NaCl (Salsol-A, 
Teva Pharmaceutical Works Ltd., Hungary) containing 
0.01 M aqueous acetic acid at a stock concentration of 
100 µM. Based on previous studies, compounds were used 
in 5 µM concentration [33, 51].
Determination of cell viability by MTS assay
Cells were seeded into a 96-well plate at the 
density of 10.000 cells/well in complete growth medium 
and incubated for 24 hours. Afterwards, medium was 
completely replaced with 5 µM cytotoxic compound-
containing growth medium and cells were incubated 
for additional 24 hours. Subsequently, MTS assay was 
performed in order to quantify viable cells (CellTiter 96 
AQueous One Solution Assay Assay (Promega, Madison, 
WI). The assay was done according to the manufacturer’s 
protocol. All treatments were performed in hexaplicates (n 
= 6). Absorbance was measured at 490 nm in a FLUOstar 
Optima Counter (BMG Labtech GmbH, Germany). Values 
were expressed relative to the control.
Treatment of OCM3 cells and RNA isolation
OCM3 cells were seeded and cultured in T25 cell 
culture flasks for 24 hours, until forming a confluent 
monolayer. Next day the medium was discarded and 
replaced with either 5 µM AEZS-108, DOX or D-Lys6 
LH-RH analog containing complete growth medium. Cells 
were incubated for additional 24 hours. The treatment 
was performed in biological replicates (n = 3). Total 
RNA was isolated from treated and untreated (control) 
OCM3 cells by TRI Reagent (MRC, USA) according to 
the manufacturer’s instructions. The homogenization of 
the tissue samples was performed with TissueRuptor® 
(Qiagen, Germany). RNA isolation process were carried 
out as previously described [52].
RT- PCR and qRT-PCR with OCM3 samples
Gene expression changes induced by treatment in 
the OCM3 cells were evaluated after RT-PCR. 500 ng of 
total RNA from each sample was transcribed into cDNA 
IScript Reverse Transcriptase Kit (Bio-Rad Laboratories, 
USA) respectively, according to the manufacturer’s 
instructions.
In order to investigate the expression of genes 
involved in angiogenesis and metastasis regulatory factors 
after treatment of OCM3 cells with cytotoxic AEZS-108, 
Human Angiogenesis 96 StellArray™ (Lonza Ltd., USA) 
plates and SYBR Green Supermix (Bio-Rad Laboratories, 
USA) were used according to the manufacturer’s protocol. 
qRT-PCR arrays were performed with untreated and 
AEZS-108- treated OCM3 samples in biological replicates 
(n = 3). Samples were subjected to an initial anellation step 
(50°C for 2 min) followed by the activation of enzyme 
(95°C for 3 min), then 40 cycles of amplification (95°C for 
15 sec, 60°C for 1 min) and 81 cycles of melting curves 
(55°C – 98°C for 0.5 min/°C). Results were normalized by 
the Global Pattern Recognition algorithm (Bar Harbor Bio 
Technology Inc.’s, USA) and quantified by ΔΔCt method.
Based on the results of the array, particularly, the 
expression of MASPIN tumor suppressor gene has been 
further investigated after treatment with AEZS-108, 
DOX or D-Lys6 LHRH using SYBR Green Supermix 
(Bio-Rad Laboratories, USA) in a 20 µl total volume 
according to the manufacturer’s instructions. The 
following primer pair has been used for MASPIN: 5′ 
-TCAACAAGACAGACACCAAACC - 3′ (sense), 5′- 
GGAACTCATCCTCCACATCCT - 3′ (Sigma-Aldrich 
Corporation, USA). Primers were designed using 
Primer3web softwer. PCR cycles were run as described in 
the qRT-PCR array experiment. Gene expression has been 
quantified by the 40- CT method. Results were normalized 
to the expression of β-actin and HPRT housekeeping 
genes. cDNA sample from HaCaT cells was used as a 
positive control and no template control (NTC) to detect 
potential contaminations in the reactions. PCR cycles have 
been performed using the Bio-Rad C1000™ Thermal 
Cycler and the Bio-Rad MyiQ2™ Real Time qPCR (Bio-
Rad Laboratories, USA) instruments.
RNA isolation and reverse transciption of human 
tissue samples
Human uveal melanoma specimens were obtained 
from 18 patients, 30–84 years old at the time of 
enucleation. Three normal uvea samples were collected 
from healthy patients after severe eye accident. After 
surgical removal, selected portions of the tissues 
were snap-frozen and stored at –70°C. In all cases, 
histopathological examination confirmed the diagnosis. 
Total RNA was isolated using the AllPrep DNA/RNA/
Protein Mini kit (Qiagen, Germany). 500 ng RNA from 
each sample was reverse transcribed into cDNA by 
QuantiTect Reverse Transcription kit (Qiagen, Germany) 
according to the manufacturer’s instructions.
Detection of MASPIN with RT-PCR in human 
uveal melanoma and healthy uvea tissue 
specimens
Based on our qRT-PCR results, the gene expression 
of MASPIN (SERPINB5) has been further examined 
in human uveal melanoma and healthy human uvea 
specimens. The following primer pairs were used: 
5′ - GGCAATGTCCTCTTCTCTCC - 3′ (sense), 5′- 
GCCGCTTGATTAGTTTCAGT - 3′ (antisense) (Sigma-
Aldrich Corporation, USA). Primers were designed using 
Primer3web softwer. 1 μl of the cDNA was amplified in 
25 μl solution containing 1.5 mM MgCl2, 1xPCR buffer 
(Fermentas, Germany), 0.3 mM of each deoxynucleotide 
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(Promega, Germany), 1 unit of DNA polymerase 
(Fermentas, Germany) and 0.1 μM of each primer. Samples 
were subjected to an initial denaturation (95°C for 3 min) 
followed by 35 cycles of amplification (95°C for 45 sec, 
60°C for 30 sec, 72°C for 1.5 min) and a final elongation 
step (72°C for 10 min). As positive control we used HaCaT 
cDNA samples. No template control (NTC) has been used 
to detect potential contaminations in the reactions. 10 μl of 
each amplification reaction was then electrophoretically 
separated on 1.5% agarose gel, stained with GelRed 
(Biotinum, USA), and visualized under UV light.
Protein analysis
Total protein was isolated from untreated, AEZS-
108- or DOX-treated cells using TRI Reagent (MRC, 
USA) and purified with isopropyl alcohol (Sigma-Aldrich 
Corporation, USA), 300 mM guanidine-hydrochloride 
(Amresco, VWR) and 96% ethanol (Scharlab, Hungary) 
according to the manufacturer’s instructions. The final 
pellet was resuspended in 1% SDS buffer containing 
protease inhibitors; 0.4% (v/v) aprotinin (Sigma-Aldrich 
Corporation, USA), 2 μg/ml pepstatin A (Sigma-Aldrich 
Corporation, USA) and leupeptin (Sigma-Aldrich 
Corporation, USA) and stored until use at –80°C. Protein 
concentration was determined by Bradford method [53, 
54]. 40 µg protein has been separated on 12% SDS PAGE 
and transferred to PVDF or nitrocellulose membrane. 
5% nonfat dry milk or BSA has been used as blocking 
agent in Tris buffered saline containing 0.1% Tween-20. 
Primary antibodies (Santa Cruz Biotechnology, USA 
and Cell Signaling Technology, USA) were applied 
at the following concentrations: MASPIN (C-8; sc-
271694) in 1:100; HIF1A (HIF1A (H-206; sc-10790) 
in 1:200; VEGFA (VEGF (A-20; sc-152) in 1:100; 
VEGFB (VEGFB (MM0008-7B43; sc-101581) in 
1:200 and GAPDH (D16H11 XP(R)) in 1:1000. Primary 
antibodies were stained with alkaline-phosphatase or 
horseradish-peroxidase conjugated secondary antibodies 
(Santa Cruz Biotechnology, USA) and detected using 
AP Conjugate Substrate Kit (Bio-Rad Laboratories, 
USA) or WesternBright™ ECL Substrate Kit (Advanstra 
Corporation, USA). Results were acquired and analyzed 
with the Molecular Image Chemidoc XRS+ System using 
Image Lab Software 5.2 (Bio-Rad Laboratories, USA).
Statistical analysis
Data were analyzed by Students’s t-test or one-way 
ANOVA followed by Tukey post hoc test to determine the 
differences between the selected groups using the program 
Prism 5 software (GraphPad Software, Inc., USA) and with 
IBM SPSS Statistics (IBM Corp. Released 2014. IBM SPSS 
Statistics for Windows, Version 23.0. Armonk, NY: IBM 
Corp.). Data are presented as a mean value ± standard error 
of the mean (SEM). A p value *<0.05 was considered to be 
statistically significant (p value **<0.01: highly significant, 
p value ***<0.005: extremely significant).
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